Podcast appearances and mentions of bob mayer

From its roots as a railyard, through many changes, an association with P.T. Barnum, MURDER! & its move uptown, Madison Square Garden has always been at the forefront of entertainment and style! Early on, the guys reference an article by Bob Mayer, which you can read here! It gives more detail about the changes through the years. Ray delved into the various images of MSG, as it changed and moved, and has put together a cool blog about it. There's really more info than one episode or blog can cover, but it is a start. It also opens the door for other venues, although the boys have done an episode about the great CBGBs, which is also a Game Changer, for sure! One of the main things that happen at MSG are concerts, and in the second half, Markus and Ray discuss a shit ton of the concerts that have happened there, including some of their own experiences. From opening night through to today, it's all about The Gah-den!!! Learn more about your ad choices. Visit megaphone.fm/adchoices

From its roots as a railyard, through many changes, an association with P.T. Barnum, MURDER! & its move uptown, Madison Square Garden has always been at the forefront of entertainment and style! Early on, the guys reference an article by Bob Mayer, which you can read here! It gives more detail about the changes through the years. Ray delved into the various images of MSG, as it changed and moved, and has put together a cool blog about it. There's really more info than one episode or blog can cover, but it is a start. It also opens the door for other venues, although the boys have done an episode about the great CBGBs, which is also a Game Changer, for sure! One of the main things that happen at MSG are concerts, and in the second half, Markus and Ray discuss a shit ton of the concerts that have happened there, including some of their own experiences. From opening night through to today, it's all about The Gah-den!!! Learn more about your ad choices. Visit megaphone.fm/adchoices

Don't have time for terrible

Don't have time for terrible ❤️

New season, new format, same nonsense. This episode is all genetically modified animals all the time.  Panel discussion on Palladium Books' After the Bomb RPG featuring Daniel (Bandit's Keep), Joe (Hindsightless), Joe (Raven God Games), KR (DnD Homebrew) Two book recommendations, Synbat by Bob Mayer and Watchers by Dean Koontz Finally we end with a spoiler filled review of 1993's horror comedy film Man's Best Friend with Joe (Hindsightless) GoodBadFlicks featurette ⁠https://youtu.be/e2z-OgXtLeE?si=4K_aGfkzxTbOFAri⁠ Humane Hollywood ⁠https://humanehollywood.org/production/mans-best-friend⁠ Ways to contact me: Google Voice Number for US callers: (540) 445-1145 Speakpipe for international callers: ⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.speakpipe.com/NerdsRPGVarietyCast⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ The podcast's email at nerdsrpgvarietycast 'at' gmail 'dot' com  Find me on a variety of discords including the Audio Dungeon Discord. Invite for the Audio Dungeon Discord ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://discord.gg/j5H8hGr⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  PLAY web forum⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.dekahedron.com/boards/index.php⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Home page for this show ⁠⁠⁠⁠⁠https://nerdsrpgvarietycast.carrd.co⁠⁠⁠⁠⁠  Blog ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://nerdsrpgvarietycast.com/⁠⁠⁠⁠⁠  Home page for Cerebrevore, the TTRPG panel discussion podcast ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://cerebrevore.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Proud member of the Grog-talk Empire  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.grogcon.com/podcast/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Ray Otus did the coffee cup  art for this show, you can find his blog at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://rayotus.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  TJ provides music for my show.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/jason376/message

Bob Mayer is an investor and entrepreneur in the Kansas City area and has a ton of experience regarding real estate investing, investing in historic properties, grants from the government and foundations, how to save money when investing in real estate, mentorship for investing, and so much more. If you're looking to learn about house flipping, rental properties, commercial property investing, how to scale your business, and how to become a successful entrepreneur, this podcast is for you. If you're curious about real estate investing mentorship, click the link below and get started today! FOLLOW ME: Youtube: https://www.youtube.com/@TroyKearns Instagram: https://www.instagram.com/troykearnschannel/?hl=en Facebook: https://www.facebook.com/thetroykearns/ TikTok: https://www.tiktok.com/@troykearnschannel?lang=en Website: http://troykearns.com/ NOT INVESTMENT, FINANCIAL, LEGAL OR TAX ADVICE

In this podcast episode Stefano Puntoni, PhD, Wharton Professor in Marketing, Behavioral Scientist, and a renowned, award-winning expert in Data Analytics, Economics, Brand Management, and Consumer Research, reveals his lessons and views on making stronger decisions as humans alone as well as together with AI and technology or data with purpose in an unpredictable world. He deconstructs the decision making process and explains why outcomes alone are irrelevant, providing real world examples from the perspectives of an individual business executive, organization, and a consumer. Most of his ongoing research investigates how new technology is changing consumption and society - a very timely subject today, and he speaks about the role of decision driven science in radically innovative companies as well as an exciting new research initiative at The Wharton School which will stimulate more insights on the relationship between new technology and consumer behaviors. 2:34 Inspiration to study both human behavior through marketing and data analytics 2:43 Early passion for architecture and enjoyment of applying both creativity and analytics using both sides of his brain at work 5:22 How the most innovative companies identify the unspoken needs 5:58 Difference between being market driven or market driving in radical innovation 9:03 Creating the bridge between the person who best understands the problem and one who understands the numbers 12:51 Unilever or Google are companies that are very advanced in combining domain experts with data scientists. Google is using consultative selling to improve their customer experience. 13:42 Ian Brown, Stanford Professor - "You can't judge decisions on outcomes alone" 14:15 How to make the best decisions most quickly and at the right time 17:01 How can we train our intuition to make better decisions? Einstein: "The intuitive mind is a sacred gift and the rational mind is a servant. We have created a society that honors the servant but has forgotten the gift". 21:20 Gird Gigerenzer: Intuition is instinctively knowing what to discard and what is not essential. 22:06 How do you utilize AI or technology to make the right decisions on determining your audience? 22:36 Why very few real advertisers who know how to really do it well and reproduce their results 26:44 Pharma case study of interpreting analytics from Medical Education programs delivered via social media 27:21 Problem-based learning in pharma is very effective - "WhatsApp" case studies in emergency care medicine 28:22 Story of an Ad Campaign with the right SEO algorithm for Health Insurance Marketplace that deceived and misled many patients in the U.S. 29:49 Tips for consumers can to make better decisions 31:36 How objective quality of marketed products relates to consumer reviews and prices 32:43 Stefano Puntoni is Co-Director with Bob Mayer of a new "Impact of Technology" research initiative at The Wharton School to promote and stimulate the impact of behavioral science work on technology across different industries

Worried about your spouse hiding Crypto, and do you not understand the metaverse, FTX, or NFTs? Listen to this episode with Bob and me! Bob Mayer is the owner and founder of Twenty Second Consulting, LLC. He has close to 20 years of experience in starting, running, and consulting businesses in various fields. He has nine blockchain, cryptocurrency, and NFT-related certifications and advises high-net-worth individuals and companies on those topics. He is a writer and soon-to-be published author, and he lives on a farm in Western Massachusetts with his wife, Carrie. Some questions answered today: Is crypto easy to hide? How do you explain NFT's and FTX? How do you diversify crypto? What could Tom and Giselle have done differently? More information about Tom and Giselle's current situation: Tom Brady and Giselle Bundchen

5 hours!

Don't have time to waste on terrible books? Kim and Aimee help you out with a review of ‘Wild Ride', a paranormal-romance-mystery-comedy (ish?) set in an amusement park, by Jennifer Cruisie and Bob Mayer. (With reference to Episode 73, Jennifer Cruisie's ‘Maybe This Time')

In part one of a two-part conversation, Drs. Patrick Loehrer and David Johnson sit down with Dr. Deborah Schrag to discuss her roles as a leader, researcher, oncologist and public health expert. The current Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, Dr. Schrag discusses the joy and passion she has found throughout her career, and more. If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at education@asco.org.   TRANSCRIPT Dr. Pat Loehrer: I'm Pat Loehrer. I'm the Director of the Center of Global Oncology and Health Equity at Indiana University. Dr. David Johnson: Yes. And hello, I'm David Johnson. I'm at UT Southwestern in Dallas, Texas. Dr. Pat Loehrer: And welcome to another version of Oncology, Etc. Dr. David Johnson: Yeah, great guest today, before we get started with our guests, though, Pat, what are you reading these days? What can you recommend to me? Dr. Pat Loehrer: Well, I'm reading Jamie Raskin's book, which is about his son and about the insurrection. It's really a wonderful read so far, particularly I think about the family nature and how much he deeply respected his son who unfortunately committed suicide. Dr. David Johnson: Right before one of the impeachment trials as I recall, right? Dr. Pat Loehrer: It was right before the January 6 insurrection. Dr. David Johnson: Yeah, terrible situation. I have a book I've been meaning to recommend for a while. It's one that I've given to all the chief residents I've worked with over the last several years. And today's guests made me think about this book. It's entitled, Osler: Inspirations from a Great Physician. It's written by Charles Bryan, who's the former Chair of Medicine at the University of South Carolina in Columbia. Dr. Pat Loehrer: You trained with Osler, didn't you? Dr. David Johnson: I was a couple of years behind him. He was my senior resident. For anyone who's an Oslerphile, it's a great book to have. But even if you're not, it's got some wonderful lessons to be learned about how to interact with one's colleagues, and a lot of information about leadership, which is why it made me think of today's guest, Dr. Deborah Schrag who we're really excited to welcome to Oncology, Etc. Dr. Schrag is the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York. She's a highly accomplished healthcare leader, clinician-researcher, and expert in public health and population science. Deborah received her medical degree from Columbia University and completed her residency in internal medicine at Brigham and Women's. She obtained her medical oncology training at Dana-Farber in Boston and also received an MPH degree from the Harvard School of Public Health. After a brief stint on the faculty at DFCI and Brigham and Women's, she joined the division of gastrointestinal Oncology at Memorial Sloan Kettering, where she was an associate member and Associate Professor of Public Health and Medicine. In 2007, I believe it was, she returned to Dana-Farber and Brigham, where she continued her work focused on improving the delivery, quality, and effectiveness of cancer care. While there, she served as chief of the Division of Population Sciences until this past year when she returned to Memorial to chair the Department of Medicine. I also think she's the first woman to hold this position, but we'll learn about that momentarily. Deb is internationally recognized as a pioneer for her work engaging patients in reporting outcomes as a way to improve care. She has led pragmatic trials using informatics strategies to optimize patient and clinician wellbeing, efficiency and quality, and equity of care. In short, she's a true superstar, leading the department, the major department, in one of the world's foremost Cancer Institutes. Deb, welcome to Oncology, Etc. Thank you so much for accepting our invitation. This is a relatively new oncology podcast, but already, we're known for our incisive, deeply penetrating questions. So, I have a question for you to start off. Do you have any carpentry skills? Dr. Deborah Schrag: Absolutely none whatsoever, Dave. None. Dr. David Johnson: I'm disappointed. It's my understanding that Schrag is German for cross or a slant and people who build cross-legged tables. So, I was hoping, my house was destroyed recently, and I'm looking for replacement furniture, and I was hoping you might be able to help me. Dr. Deborah Schrag: I apologize. But I'm not going to be able to help. The name, you're correct, though, David, is a German name. So, my family does hail from Germany and they made malt, which is the major ingredient in beer. I'm not sure where the name comes from. But they ran malt factories and shipped malt all over to all the beer, before there were craft beer distilleries, that's what they did. Dr. Pat Loehrer: That may come in handy by the end of this podcast, by the way. Dr. Deborah Schrag: Could be. Dr. David Johnson: Well, speaking of your family, tell us a little bit about your background and where you were raised, and your family members. Dr. Deborah Schrag: Sure! I'm glad you asked that because I really have been very influenced by where I grew up. And as I think about it, experiences that go back to first grade got me where I am today. So, I am from New York City. I grew up in Manhattan in the 1970s. And as you may know, that was a pretty rough time in the history of New York, what's often referred to as the 'bad old days', although it didn't feel that way to me. But I started out attending New York City public schools. And at that time in my neighborhood on the Upper West Side of Manhattan, my first-grade class had about 45 students, and one teacher, there were about five or six of us who spoke English, and everyone else was a recent Puerto Rican immigrant. I pretty much sat in the corner and read to myself. Now I didn't stay in the public school system for long, but I saw in first grade, how things weren't fair. And I saw and felt my own privilege, acutely. And even as a little kid, I had that sense. Eventually, my parents transferred me to private school later on. And there were kids in the neighborhood who didn't have the same privileges that I did. But living in New York, you walk around, you're confronted with disparities every day. We still see it today with homelessness on the streets. At that time, there was a lot of alcoholism and the use of drugs. And they were two blocks north that were safe to walk and two blocks east that were not safe to walk. So, this really stuck with me from a very early age. As a student in summer jobs, I worked lots of interesting jobs. I started at 14 scooping ice cream at Baskin Robbins, I worked at a famous Deli in New York called Zabar's, selling coffee. Lots of interesting jobs that I worked during holidays and vacation times. But one of my first jobs was working in an organization called the Floating Hospital, which was a big old ferry boat that circumnavigated Manhattan, and it provided a summer camp. And we would take 1800 people on a boat around Manhattan every day. And my job was to do lead testing. And I learned how to stick kids, test them for lead because there were incredible amounts of lead poisoning in New York City in the early 1980s. And then we would work on tracing the kids and these were toddlers, two-year-old, three years old. There were many families who were living in homeless shelters in New York City in the early 1980s. And that was really the beginning of my interest in public health and inequities. And really the marriage of medicine and public health. That had a deep and long-lasting impression on me and really stayed with me throughout my career. That early experience, I think it propelled me into medicine and to medical school and also to marry medicine and public health. Dr. Pat Loehrer: Tell me a little bit, Deb, about your parents. Dr. Deborah Schrag: Sure! My mother was born in the United States. She was a teacher who many years later after having three children went to law school and she became a litigator. And actually, her boss was Rudolph Giuliani. My father is a child of World War II. He was a child of German Jewish parents who had to flee the Nazis. Probably the most interesting story is that my paternal grandfather was an OB-GYN. So, I am a fifth-generation physician. My paternal grandfather was an OB-GYN at Charité, which is a very famous Hospital in Berlin. He was the head of OB-GYN there in the 1930s. But he had, I think he was half Jewish, and the Gestapo asked him to leave and he had to leave. He was an expert in version, which is essentially flipping babies and the setting of placenta previa. He then left for Lebanon, where he was in the French Resistance and had a thriving OB-GYN practice in Beirut, Lebanon, during World War II. And at night, there was a curfew, and he was part of the resistance and passed secrets around from the Russians to the French, so very dramatic. My father was born in this setting, and arrived as a new immigrant to the United States in the 1940s, where it was very hard to be a child whose parents had a German accent, given the prejudice against Germans at that time, but also went to New York City public schools, had a tremendous opportunity. It's really kind of the classic New York immigrant success story. You know, arrived in the United States with the shirts on their back and managed to work their way to a better life and achieve success and good education through public education for all their offspring. I will also say that my father had a public health stint. He worked in North Carolina as an alternative to going and serving in the Vietnam War, he was in the Public Health Service. And he worked in North Carolina in the textile mills and worked on a disease called byssinosis, which is also known as the brown lung. It's an occupational health disease that affects textile mill workers. As a child, I spent many dinners, hearing about byssinosis and brown lung, and black lung. I think at an early age I really came to understand how the world wasn't fair, and how it was instilled in me early on that it was important to work to try to make things better, particularly for people who didn't have privilege. And I think when you come from an immigrant family, and you realize how much privilege has been bestowed on you, that really leaves an indelible mark. I have to say, as Chair of Medicine at MSK, it is staggering to me the proportion of faculty here at MSK, but also at Dana-Farber, where I worked previously, we have lots and lots of immigrants who've been able to accomplish just amazing things through just motivation and drive and energy and creativity. And so, I'm a big believer in how much immigrants have powered this country. Dr. Pat Loehrer: Deborah, are your parents still alive? Dr. Deborah Schrag: My parents are still alive. They're both in their early 80s. And they both still live on the Upper West Side of Manhattan. So, I'm very privileged and fortunate to have living parents. Dr. Pat Loehrer: I can imagine the pride that they have for you. Dr. David Johnson: I just want to jump in and let our listeners know that Deb mentioned Charité in Berlin. That's the home of multiple Nobel laureates that all of us would know like Ernst Chain, who was one of the individuals involved in the development of penicillin, but Paul Ehrlich, Robert Koch, Hans Krebs, and for cancer doctors, Otto Warburg, among others. So, it truly is a world-renowned institution. Dr. Deborah Schrag: Well, my paternal grandfather was famous for this technique called version, which essentially involves putting your stethoscope next to the uterus, figuring out where the placenta was, and then essentially trying to flip the baby without disrupting the placenta or causing any harm, which required incredible skills with a stethoscope because you had to appreciate, I guess, the placental vessels. I'm not aware that this skill is still in existence, it was an important skill to have in the 1930s. When, if you did a C-section, there was a high probability of endometritis. So, you could save the baby, but you would often lose mom to endometritis. Or you could save mom, but you might not save the baby. So, at that time it was a big deal, but thankfully no longer. Dr. David Johnson: This is why we call it an Oncology, Etc. Our listeners didn't know that we're gonna get OB information in this particular podcast. Dr. Deborah Schrag: Or a digression on the history of medicine. I do find that, you know, I am inspired by the generations that came before me. I think it's also true that there are many physicians who are first-generation physicians in their families and some of us are privileged to have lots of healthcare professionals and sort of feel it as a calling. Dr. David Johnson: I think of you with many, many talents. But one of the things that I think stood out to me is, many years ago, you were in the van, talking about the financial cost of health care. I remember a very influential paper you wrote in the New England Journal, talking about the cost of treating GI cancer, colon cancer in particular. But where did your interest in that particular aspect of health care begin? What was the stimulus there? I mean, obviously you had a lot of stimulus from your family. What else? Dr. Deborah Schrag: That's really interesting. This is a little bit of a history of oncology. At that time, I was an assistant professor and assistant attending in the GI oncology service, seeing lots of patients with colorectal cancer. And we were working on a clinical trial of a drug called ImClone C225. And that was the name of the protocol. And we were putting patients in that clinical trial. And you know what? This drug was working. We were getting excited and the drug was moving ahead. We looked at the Phase 1 data and we launched Phase 2. We had meetings with the research protocol nurse and the research assistants, team meetings, and I would say there were about 50 people who were aware between the GI oncologists and the nurses and all the research assistants. You guys know that it takes a village and even though the villages were smaller then and it wasn't a particularly large trial, there are many, many people involved and everyone had the sense that this drug might be working. Just for context for our younger listeners, this is back in the early aughts, and basically, the drug that we had to treat colorectal cancer was 5-FU in many different formats and Irinotecan. And that was it. Some people thought mitomycin might work a little bit, but it was so horrible that it really barely worked. But that was what we had in our bag of tricks. So, the fact that we had this ImClone drug that eventually came to be known as Cetuximab, was remarkable. So, here's what happened. It turned out that this is the drug made by the company ImClone. And there were some shenanigans, some insider trading. And one of the people caught up in insider trading, in addition to some people involved with the company itself was none other than Martha Stewart, sort of the famous homemaker who still publishes magazines to this day. And you may know that she actually did some time in federal prison as a result of insider trading on this drug. I remember being a junior attending, and all the people involved in the trial and all the cancer professionals, we all knew this was working. But everyone respected the confidentiality of the situation, of the patients, and all the integrity that goes into academic medicine. And I remain inspired by the integrity of all the professionals, the doctors, the residents. These were not affluent people. I can tell you. we were not paying research assistants a whole hunk of money. They investigated every trade made by this company. There were absolutely no shenanigans or improprieties from the hard-working folks who helped bring this drug to market. So, as this was going on, we had many patients who were not eligible for the trial who were interested in getting the trial. So, of course, we followed as this drug got FDA approved and came to market. You could check me but I believe it was February 2004, it was FDA approved. It came out with a huge price tag. It was approximately $10,000 per month. I was mad because I was taking care of regular New Yorkers at that point. I had public school teachers, I had patients on Medicare and they couldn't afford the 20% copay. Because $10,000 a month for Cetuximab, if you have a 20% copay and you're New York City, public school cafeteria worker, is not yet eligible for Medicare with a typical plan that a New York City public school system employee would have, that was $2,000 a month. And that did not work for one of my patients who is essentially what we used to call a lunch lady. I was so mad that I decided to channel that anger into writing what I think is a perspective for the New England Journal called, “The Price Tag on Progress”. I wrote that piece. I know that many, many people and many of my esteemed colleagues have continued to work in that area and do research on the economics of drug pricing and there are many, many experts. I didn't stick with that. Not that it's not interesting, and not that it's not important. It's incredibly interesting and important, but I felt that the solution needed to happen in the legislature, state legislature, federal legislature. I think that this is about social policies, and we need to advocate for appropriate health insurance programs to make it possible for people to get coverage when they have catastrophic illnesses, and we need to think about the entire approach to drug pricing in this country. I still think that's important. I'm not convinced that what we need is more research on the topic. I think we need more policymaking and laws on the topic. I think we're still dealing with this. I'm sad to say that it's been nearly 20 years since I wrote that perspective. But I think it was motivated by frustration, not being able to get my patient what she needed, and many patients thereafter. And just the incongruity between some people benefiting from insider trading and all the good people who were doing the right thing. Dr. Pat Loehrer: I just want to throw in one thing if I can. Len Saltz, who's one of your partners, it was a piece of that trial that he presented at ASCO talking about ImClone C225. And ironically, it had a 22.5% response rate. And Len said, it's a bummer that ImClone didn't call it C995. Dr. Deborah Schrag: You have no idea how often we used to talk about that, joke about that in the clinic. I have another good story about that drug, which I think really illustrates something I believe and I think it's actually something that Osler said but it's also something I have to say I learned from both of you. And it has to do with listening to your patient. So, I had a patient named Matthew, who was a young man, 34 years old. He walked into my clinic with a diagnosis of diffuse metastatic colorectal cancer with multiple bilateral pulmonary metastases, which came to light when his tennis game was off. He was, at that time, an early employee of a newly started company called Google. And he was working on advertising algorithms, and Matt got the drug Cetuximab. And unfortunately, he was on it for quite some time. He was on it for about five or six months. But eventually, it was pretty clear that we were coming to the end of the road. And he and his wife planned a vacation. This was part of his end-of-life process planning. It was their fifth wedding anniversary in the Berkshires. We worked so hard to get Matt to the Berkshires to a beautiful inn, and on Saturday night, my pager goes off, and Matt cannot sit up. He's weak. And he'd been complaining of terrible fatigue for weeks, to me, and I really hadn't quite figured out why Matt was so fatigued. I mean, I just didn't understand it. And we get into this inn and I get a call from the Berkshire Medical Center, a small community hospital, 'Dr. Schrag, your patient is here. He's so weak and he can't sit up.' 'What's going on?' The ER doctor says, 'Well, he has a Chvostek sign', which is a sign of severe hypocalcemia. 'So, call me back with the calcium.' The calcium is low. Well, I think those of your listeners who are closer to medical school know that when the calcium is low, you have to check the mag. And Matt's magnesium was 0.2. And he got some magnesium in the Berkshire Medical Center. And all of a sudden, he felt great. He was able to go on and enjoy the second half of his fifth anniversary weekend at the Berkshire Inn and he came back. And I felt terrible because he'd been complaining to me of fatigue for six weeks and I hadn't checked his magnesium. I was like, 50 bilateral pulmonary metastases on chemotherapy. That's a fatigue explanation. Suffice it to say that we went on to start checking magnesium on everyone getting Cetuximab. Now mind you, the drug is FDA approved and FDA labeled at this point. So, we started checking magnesium, and we find that it was low. I start getting on the phone and calling my mentors. I called Dr. Bob Mayer, who was the head of my fellowship director and was like a revered mentor to me. 'Hey, Bob, does anyone up there in Boston have low magnesium from Cetuximab?' 'We don't check magnesium.' I said, 'But can you check?' I started calling around and that's a great example of the community of oncology. We are a community. I just started working the phones and calling friends and saying 'You guys checking magnesium for any of these folks on Cetuximab?' Suffice it to say, we figured out that their EGFR receptors in the ascending loop of Henle - so, again, back to biology and pathophysiology - the drug Cetuximab was blocking reabsorption of magnesium in the kidney, and it was Cetuximab that caused a terrible magnesium wasting. Oral magnesium did not work. You had to give it intravenously, repeatedly. And we helped eliminate fatigue for a bunch of patients. About six months later, I showed up at ASCO with these little cardboard slides and a little poster back in the corner and put up our little case series, very little. But I'm proud to say that we changed the label of Cetuximab and it's now on the label that it causes hypomagnesemia. It might be one of my more cited papers, paradoxically. But I think it's a principle that really has stuck with me, and I've tried to impart it to all the students and residents and fellows, 'Listen to your patients because - I think it comes from Osler- they're telling you something. We have to pay attention.' Again, I have never forgotten that. But really listening and trying to figure out how we can use our understanding of pathophysiology and what our patients tell us to ask questions and not just accept dogma and try to figure out what we can do. And you know, I couldn't have figured that out on my own. I happened to find a really smart nephrologist who happened to be able to sort of go to animal models and knew the right studies and the right people to talk to. Dr. David Johnson: It's one of the reasons why we are a multidisciplinary specialty. And we use the expertise of our colleagues. I think that's such a wonderful example of listening to one's patient and it really profoundly impacted our understanding of how that drug works and renal physiology, actually. That wraps up part one of our interview with Dr. Deborah Schrag, Chair of Medicine at Memorial Sloan Kettering Cancer Center. We hope you've enjoyed learning about her background and her early career. In part two of our conversation, Dr. Schrag will discuss her programmatic goals at Memorial Sloan Kettering, the importance of mentorship and leadership, and what it means to have joy in the profession of medicine, and, frankly, much more. So, please be sure to join us. As always, we want to thank you for tuning in to Oncology, Etc. an ASCO educational podcast, where we will talk about just about anything and everything. So, if you have an idea for our topic or a guest, please email us at education@asco.org. Unknown Speaker: Thank you for listening to the ASCO Education Podcast. To stay up to date with the latest episodes, please click subscribe. Let us know what you think by leaving a review. For more information, visit the comprehensive education center at education.asco.org.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.

New York Times bestselling author, is a graduate of West Point and former Green Beret. He's had over 80 books published, including the #1 bestselling series Green Berets, Time Patrol, Area 51, and Atlantis. He's sold over 5 million books. He was born in the Bronx and has traveled the world. He's lived on an island off the east coast, an island off the west coast, in the Rocky Mountains, the Smoky Mountains and other places, including time in East Asia studying martial arts. He was an instructor and course developer/writer for years at the JFK Special Warfare Center and School which trains Green Berets and also runs the SERE school: Survival, Evasion, Resistance and Escape.

SHOW NOTES Dear Friends of the Soul Care Podcast: I love hanging out with smart people.  That's what happened in this conversation with Dr. Bob Mayer. We talked about how the Bible has become a club which we have weaponized to beat one another up with these days.  We quote a Scripture; use a Bible verse to prove our point and to establish a basis of believing rather than accepting the Bible as a book of rescue stories.  Bob Mayer explains that the Bible is a book of rescue stories.  Stories --that help us in our own rescue to come home. When we unlearn what may have gathered as "fact" about our view of what the Bible and relearn that the Bible is a spiritual book and must be learned in a spiritual way.  You'll want to listen to this with a pen in hand and paper to take some notes. It's like going back to school. And this is the reason I really like THIS podcast.  We need to unlearn and relearn so much because so much is not working for us anymore.  THIS conversation will help you so much and I hope you'll listen in and join the conversation where the soul meets the world.  As you listen, Bob's trusted voice will become a beacon to help you find your way home about what you will WANT to believe about the Bible. The Bible is a series of stories about a rescue mission with the similar them of a loving God who wants us to come home!  We are all slow learners--I know I am. This particular podcast is foundational and so very important. I commend it to you. As you listen this week, Gwen and I will be on retreat with a brand new cohort of men and women who will begin a two year journey with the Soul Care Institute. We'd appreciate your prayers .  Every blessing dear friends!  Steve   SPECIAL GUEST DR. ROBERT MAYER Dr. Mayer joined Gordon-Conwell in 1997 as Senior Librarian and Director of the Gordon-Conwell libraries, and Director of the Harold Lindsell Library at the Charlotte campus. Dr. Mayer’s scholarly interests include American church history, Advent Christian Church history and theology, and 20th century American evangelicalism - with a B.S. at the University of San Francisco; M.A. at Fuller Theological Seminary; D.Min. at Gordon-Conwell Theological Seminary and an MLIS at the University of North Carolina at Greensboro. He enjoys visiting historical sites, which he does often with his wife, Renee, and has been an avid supporter of the San Francisco 49ers football team since he was nine. His other personal interests include collecting campaign buttons (of which he has over 70) and attending concerts and the theater.   MENTIONED IN PODCAST 2 Timothy 3: 15-16 (MSG) Shaped by the Word by Robert Mulholland Reading: Beloved is Where We Begin by Jan Richardson. Read by Joe Chambers. Ancient Words by Lynn DeShazo, performed by Michael W. Smith Lyrics       SOLO: CREATING SPACE WITH GOD by Stephen W. Smith and Peter Ivey LEARN MORE ABOUT THE BOOK!    

In this episode of ASCO eLearning's Social Determinants of Health (SDOH) series, Narjust Duma, MD, moderates a discussion with ASCO CEO, Clifford A. Hudis, MD, FACP, FASCO and Sybil R. Green, JD, RPh, MHA, Director of Strategic Initiatives in ASCO’s Policy and Advocacy Department, on what ASCO is doing as a professional society to address equity as part of its mission.  Subscribe: Apple Podcasts, Google Play | Additional resources: elearning.asco.org | Contact Us   Transcript: PRESENTER: The purpose of this podcast is to educate and inform. This is not a substitute for medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. NARJUST DUMA: Welcome, everybody, to the second episode of ASCO's Social Determinants of Health series. My name is Dr. Narjust Duma. I am an assistant professor at the University of Wisconsin and also a thoracic oncologist. Today I'm joined by ASCO's CEO, Dr. Cliff Hudis, and Sybil Green, Director of Strategic Initiatives in the policy and advocacy department for ASCO. This series is a new initiative proposed by ASCO president, Dr. Lori Pierce. It focuses on increasing oncologists' awareness about the social determinants of health through the cancer care and how impacts our patients' outcome, including modifiable risk factors. This series is inspired by Dr. Pierce's presidential team of equity, every day, every patient, everywhere. In this episode, we look at what ASCO is doing as a professional society to improve health equity and cancer care. Welcome, Dr. Hudis. Welcome, Mrs. Green. First I would like to us what is ASCO doing as an organization in the matter of health equity and cancer care? CLIFF HUDIS: So I guess I'll start here. Thank you very much for spending some time with us on this. If you look at ASCO's mission, it is conquering cancer through research, education, and the promotion of the highest quality and equitable cancer care. So the idea of equity and our responsibility to address disparities is really in our organizational DNA. I have to point out something that many people may not realize. But when ASCO was founded in 1964, one of the seven founders was a black woman, Jane C. Wright. Dr. Wright died in February of 2013. But her father was among the first African-American graduates of the Harvard Medical School. His father was also a physician. And he was educated at what became Meharry. So I remind everybody of this as often as I can, to make the point that not only do we have an opportunity to advance equity and to deal with disparities in health care, but it's my perspective as a leader of ASCO that we have a special obligation and responsibility to do all of that. So we can talk more about it. But I'll just introduce maybe the answer by saying there are really two broad themes at work for us at ASCO. One is externally facing. And one is internally facing. The externally-facing work includes a range of projects and output that we can talk about a little more, but for example our position papers describing disparities and then identifying potential steps to take to address and solve them. But it also includes support for targeted research that is meant to narrow those gaps. It includes our educational efforts, both for our members and for legislators, advocacy for policy, and so on. And then on the internal side-- and here I'll ask Sybil to talk a little bit-- I think we've recently recognized our opportunity, and again responsibility, to think about the workplace itself and to think about our staff and to think about the activities and actions we can take and the roles we can model to create a better world. So I know I've been high level in my initial answer here. But the two domains again are external and internal. And then we can talk about some of the specific projects as we go on. NARJUST DUMA: Mrs. Green, I think it's very important to share about these internal aspects of ASCO because many of us are now aware as members, we see the surface. But ASCO is a large organization with many staff and members. So it would be great that you can share that with us. SYBIL GREEN: Absolutely. And thank you for allowing us to share that. I think Dr. Hudis pointed out some of what we've done since ASCO's establishments and really charging everyone on staff to really live out that obligation of equity, diversity, and inclusion. And so through our programs, our staff have to do their work, make sure that we are creating equitable opportunities for patients and physicians, but it starts at home. And so we have to make sure that internally, we are offering those same opportunities for our staff to engage because what we know is that when staff are engaged, and they have the opportunity to bring their true selves to work every day, they bring their personalities. They bring their lived experiences. And that all plays out in the work that we're doing on behalf of members, in their patients, but also for staff. I think if I were sum up where our program is going, similar to what Dr. Hudis has done, the three components are really enabling staff success. We ought to be able to do that for our staff internally. Every day we ought to provide opportunities for them to succeed. And then making sure that our partnerships-- those that we work with, whether it's in our publications, our meetings-- making sure that our partners goals and ideals align with ASCO's values and ideals. And all of this, of course, is in support of the greater ASCO enterprise, which is our members and the patients and of course, ASCO staff. NARJUST DUMA: And I think that it's really important-- I had the pleasure of interacting with several staff members with diverse backgrounds. And I think as we develop the mentorship program and other things, their input is diverse. It means we also are able to cover the trainees needs because every trainee's needs are different. And because I cannot give a talk or do a podcast without mentioning my grandma, [INAUDIBLE], I have to say that it's important to clean your house first before you go and try to clean other people's houses. I do promise it's beautiful in a Spanish. But I think it's important that everybody knows that internally ASCO is doing a lot of work. And I think it's important to talk about the grants in health equity. And I'm mentioning this because I haven't been doing health equity since I was a med student. And sometimes you find yourself not having enough grant opportunities. Now there is an increase. But when you compare it to other areas of oncology, you may be more competitive because there are less grants. And I think it would be great to hear from the both of you about the new health equity grants, the breast cancer disparity grant, and beyond. CLIFF HUDIS: Well I would just point out something to build on your comment, first of all. Since we were founded in 1964 til now-- so just over 55 years-- we've made unbelievable advances, I think, in oncology in general. Indeed the reason I as an old man chose to go into an oncology in the 1970s was that the vision ahead was that this was going to be an exciting field. And it has not disappointed. However there's a dark that I think we should acknowledge. The advances have not been fairly or evenly distributed. And indeed in some cases when we make massive improvements in outcomes in terms of what's possible with state-of-the-art care, we increase disparities because not every group catches up. And I say all that because it's important to understand that this is not about abstraction. These grants that address that gap are as or more important than the basic science grants that actually advance the biology and understanding in the first place. One without the other is incomplete. So I can't agree more that this is important. And actually from an investment or return on investment point of view, in some ways, these grants are an even better deal because we can rest many of these gaps in care delivery and in knowledge pretty quickly and narrow the gap. And we've seen it. I'm going to give you some examples in a moment. Whereas funding basic science, honestly, is a much higher risk proposition, if you think about it. So I don't mean to set up a false competition here. But I want to point out that there's a big reward. So here's an example. The plenary session abstract at ASCO two years ago now-- abstract number one, if you recall, was no moral less than an analysis of the impact of Medicaid expansion. And what did it show? It showed that with Medicaid expansion, those states that implemented it quickly narrowed the gap in time to initiation of therapy for curable colon cancer. It's a simple take-home point. I care passionately about this personally because these are differences in outcome that have been labeled as associated with race for many years or other specific ethnic facts. But really what they're about is nothing except unfair, uneven access to care in the first place on the basis of race. And it's something that we can address. So we are building out programs to address this through a number of granting mechanisms. For 2020 alone, there are going to be two Young investigator awards that are earmarked for underrepresented populations. And there's a career development award and another YIA, Young Investigator Award, in health disparities specifically. But this is just, I think, part of the issue. The other issue for us-- and actually a commitment going back for years-- is to do something about the workforce itself. And I don't have to tell you, but of course, there is a huge disparity playing out when we look at makeup of medical students in America. And it gets accentuated to the extreme when we look at black men. They are the most disproportionately underrepresented group right now. So how are we going to address that? And we're really proud this year to be launching a program that is aimed at newly-matriculating medical students building on a successful program in Boston that's been running for a couple of years already with Bob Mayer is the founder. And our goal is to the interest of specifically targeted populations, not just in medicine but specifically in oncology. NARJUST DUMA: Mrs. Green, you would like to add something about the grant and what is happening to support health disparities various research at ASCO? SYBIL GREEN: I'll just add the importance of any grant opportunity in any program being one to two. So it's one thing to be able to address bringing in the right medical students to be able to mirror the populations that they serve. It's something else to continue to support them along the way, and so not just stopping at the students, not just stopping at the research, but also making sure that was they're in practice they're supported. And a couple of grants that we've had for some time focus on quality, not just in ensuring that quality services are delivered, but actually helping practices to determine how to identify gaps in [INAUDIBLE] populations that are underserved because we may not be able to identify those same gaps that we would identify in majority populations. And so by giving them the tools to some of the other programs that ASCO has to be able to identify those gaps and then to support them along the way is really important. NARJUST DUMA: And I want to add to what Dr. Hudis mentioned about workforce diversity because this is one of my areas of research and passion. And it's extremely important to have a diverse workforce to represent the patients we're caring for. It's not only having a diverse workforce, but having a workforce that practices cultural humility. We cannot assume that we are proficient or we are competent in somebody's culture. I'm a Latina. And there are so many Latinos in so many different backgrounds that I cannot learn them all. And I think it's important that early interventions are-- because when you get exposed to a specialty early on during the training, that would change your pathway. I'm the daughter of two surgeons. I'm supposed to be a plastic surgeon. But a patient with cancer changed my life and my pathway. So we're able to support those students that have less resources and less access-- and that also includes rural students-- they may don't be black or Latino, they may be white, but they come from rural areas with limited resources-- we are sure that we meet the patient needs because there are aspects I don't understand. Like I'm in Wisconsin, and there are some aspects to farming I didn't know. Now I know when harvest is. And all of that allows us to plan appropriately. So I can see how important it is. And there's a task force that is run by Dr. Winfield, which I'm lucky to be part, that focuses on the workforce diversity. Along those lines, as a minority in medicine, I have seen up and downs of the interest in workforce diversity and health equity. I think many events in 2020 helped a lot of people open their eyes or be more conscious like, oh, that's not isolated. That happens in my back yard. It happened in Kenosha, Wisconsin. But we want to hear how is ASCO making these things long term, how the internal and external changes are going to be long term? And I will start with Mrs. Green and then go to Dr. Hudis. SYBIL GREEN: So in terms of making it long term, it can't be one and done. I think quite often when we focus on equity and diversity issues, we always look at diversity first. And so whether it's workforce or whether it's increasing opportunities for access, you can't just look at the numbers. You have to also think a little bit deeper. You have to think about culture. And so culture with humility, like you mentioned, Dr. Duma, is important, but making sure that attitudes are changing along the way. And that happens through self-awareness. That happens through understanding. And I think that ASCO plays a real role in making sure that our members understand what the issues are and how to dig past those things and provide them with the tools to be able to [INAUDIBLE]. ASCO I think, is not unique. And the idea that this is all new to us has gotten a lot of attention because of some of the social and racial injustice. But what that means is that our members now are probably more interested in ensuring equity than ever before. But we have to teach them how to do it. We have to teach them how to speak the language. We have to teach them how to be more aware, both in their own organizations, at ASCO internally, and for their patients. And so it's a cultural change. It's not going to happen overnight. It's gradual understanding of the dynamics, gradual understanding of different peoples goals, and meeting them where they are, so that we can help them to move along, so that we can come to a more equitable and just [INAUDIBLE]. CLIFF HUDIS: I think one of the things Sybil and I spoke about this summer is we launched our internal EDI effort-- relates to this. And that is this is not about identifying a leaky pipe and patching it and saying, well, we're done now. This is actually, in my view, a permanent change in the way we see work and the way we see our growth. So the goal is to reach a specific landmark. The goal is to change how we think about our work and how we think about our role in the world, so that we're constantly improving. And it's a journey, not a destination, I think, which sounds trite. But that's the spirit of it. And it gets to your question about how we make sure that the commitment is continuous and not just while it's [INAUDIBLE] and exciting. And I think we are committed and dedicated to that. I do want to present a related challenge because it's something you said really sparked this thought for me. As a physician, when did you know that you wanted to be a physician? How old were you? NARJUST DUMA: I was 5. CLIFF HUDIS: And, Sybil, when did you know what your career path was going to be? SYBIL GREEN: I was 9. CLIFF HUDIS: That doesn't support my thesis [LAUGHS] [INAUDIBLE]. So here's the issue. The issue of burnout in medicine right now is getting a lot of attention. And one of the reasons for it, frequently given, is that doctors on average decide to commit to their careers a decade younger than most people on average commit to other careers. You're an exception, Sybil, so I should have pretested the question. But the issue is we're not here to talk about burnout today, even though that's really important. The issue is this. In order to ultimately address the makeup of the population of physicians, we need to reach deeper and further into precollege communities. And we need to show people that they could have lives in science and health care and in medicine and maybe specifically oncology. And I'm just pointing out to you that that's a daunting challenge for a professional society like ASCO. That's not our audience. We don't have a natural connection there. And one of the things that we're working on right now is identifying programs that have worked, that exposed high school students from previously excluded populations or communities to medicine, so that we can spark that passion before college, not during college, and therefore have the commitment that it takes to go far into medicine. And I'll just close by saying something that you hinted at but needs to be said. The reason to have diversity in our workforce is not that an Asian patient needs an Asian doctor. It's that an Asian patient needs a practice that has Asian doctors in it, so that the practice as a whole is able to be culturally sensitive and able to relate and communicate and support them because I think sometimes this issue gets oversimplified as well. SYBIL GREEN: So Dr. Hudis, your theory is not completely [INAUDIBLE] I think it's relevant to this conversation because while I knew what I wanted to do at 9, what I didn't have was the representatives in the community. I didn't have the mentor. Interestingly enough, I had more mentors in pharmacy than I had in law because I saw pharmacists who looked like me. I happened to live in a town where there was a historically black college with [INAUDIBLE]. And so I saw people look like me. And it made it a lot easier for me to reach out to them, for them to mentor me, for them to start talking to me about what equity in health care looked like. That really wasn't until I was in college. But the truth of the matter is for most diverse students, most minority students, that doesn't exist. And I think that that's where ASCO's mentoring programs are really rich. You have the opportunity to do that. NARJUST DUMA: And I think this is important because you can do what you can see. And that has been proven over and over again. We unfortunately are running out of time. But I want to ask the final question. Like a manuscript, like a study, everything has limitations. And I think it's important that we talk about the limitations of ASCO doing this work because realistic expectations are helpful so we don't get disappointed when we have big expectations that may not be met. So Dr. Hudis, what are some of the limitations of ASCO to help equity work now? CLIFF HUDIS: You're right, it's a huge issue. If you think about where our scientific focus is, we can measure the disparities or the difference in outcomes. And we can write a paper about that but when you really get to addressing the reasons for it, it extends far beyond what we can do. So I guess our limit is we can call attention and rally colleagues and collaborate across the House of Medicine and broadly into Congress, where we can make a difference-- or to the United Nations and World Health Organization. But we can't do this heavy lift alone. We need other colleagues who agree who are willing to invest time and money to make the change. SYBIL GREEN: And I would add partnerships because as much as we're talking about social determinants of health, we recognize that all social determinants of health are not health related. They're not [INAUDIBLE]. And many of them live and operate outside of the realm of health care. But what we can do is bring our expertise to the table about the impact of those things, so that our partners stand in their own world, in education, in criminal justice, in financial assistance, how that can help really change the outcomes for patients. I think at ASCO, we've got that expertise. And we can do that. NARJUST DUMA: Thank both of you for your time. Thank you, everybody, for joining us for the second episode of ASCO Social Determinants of Health series. Please keep up with us. You can subscribe. You can see this on Facebook, YouTube-- when it becomes available. We'll continue to explore the social determinants of health and cancer care. You can leave feedback or emails, any questions to the professional development, at asco.org. And I thank you for your time. And have a wonderful week. PRESENTER: Thank you for listening to this week's episode of the ASCO eLearning weekly podcast. To make us part of your weekly routine, click Subscribe. Let us know what you think by leaving a review. For more information, visit the comprehensive eLearning center at elearning.asco.org.

www.bobmayer.com

Prep Sports Weekly for Thursday, November 19, 2020. We start with Shorewood Assistant Girls Basketball Coach Aaron Lommers and multi-sport athlete Mia Battle. Then another 2020 inductee to the Snohomish County Sports Hall of Fame Jill Mayer, and her father Bob Mayer talk about her Special Olympics accomplishments. Finally, it's two members of the Monroe High School Class of 2021 football players Trey Lane and Brenden Rodriguez. Both were 1st Team All-Wesco in 2019.

Cleveland Indians 29-year scout Bob Mayer chats with ML about his long career, what makes a great scout, the Indians the rest of the way, what makes home games in Cleveland so special, no-doubters he has seen play the game at a young age, the analytic world we live in today and more!  

WBOI's "Tossed Jazz Salad" is a tasty mixture of that genre's styles and forms, served up every Tuesday evening by volunteer host, Bob Mayer. Mayer's teaching and performing background adds extra spice to the experience, and WBOI's Julia Meek, as part of her ongoing "Behind the Mic" series, invited him into the studio earlier this week, to discuss how his musical passions have helped him perfect this secret recipe.

Authors on the Air host Pam Stack welcomes New York Times best-selling author Bob Mayer. About Bob: Bob Mayer is a NY Times Bestselling author, graduate of West Point, former Special Operations and the feeder of two Yellow Labs, most famously Cool Gus. He's had over 75 books published and sold over 5 million, including the #1 series Area 51, The Green Berets, Atlantis and the Time Patrol. Born in the Bronx, having traveled the world, he now lives peacefully with his wife and labs. He previously wrote under multiple pen names including Robert Doherty, Greg Donegan, Joe Dalton and Bob McGuire. For more information, free ebooks, free audio and pictures of the legendary Cool Gus go www.bobmayer.com

Author Bob Mayer, AREA 51 books & Cool Gus dad on AOTA with Pam Stack.

Robert (Bob) Mayer, Alzheimer’s Association Connecticut Chapter’s Greater Hartford Area Walk Manager and Susan Seid (sigh-ed), Greater Hartford Area Walk to End Alzheimer’s 2018 Committee Member/Volunteer, awarded volunteer of the year last year will talk about upcoming Alzheimer’s walk on October 14th

Bob Mayer is a NY Times Bestselling author. He’s had over 75 books published and sold over 5 million, including the #1 series Area 51, The Green Berets, Atlantis and the Time Patrol. He was born in the Bronx, New York. Graduated from West Point and served as an officer in the 1st Cavalry Division. Bob...

This time on The ApeCast, Geoff and Jack take a look at the excellent short story collection Tales From the Forbidden Zone, specifically four of the stories: Dan Abnett's Unfired, a tale of a mutant pilgrimage to the Holy Land, Nancy Collins' More Than Human, Less Than Ape, about a young Cornelius' shocking discovery in a far-off place, Bob Mayer's The Pacing Place, an alternate sequel to the first film about Taylor building a new human community, and John Jackson Miller's Murder's Row, a quirky tale of Zira and Cornelius' run-ins with TV executives in the 1970s.  Throughout these four minisodes, they'll also touch on such subjects as mutant culture and religion, the fate of Long Island on the Planet of the Apes, show business in the 1970s, the twisted relationship between John Connor and Kyle Reese, Taylor's blood type and its implications, and so much more!   Straight from the Forbidden Zone to your sweet primate ears it comes!

Michael was diagnosed with colon cancer in June 2016 after a routine colonoscopy. He is in a clinical trial that has included surgery and chemotherapy and is still in treatment. Michael works for the US Postal Office and enjoys carpentry.Donnamarie was diagnosed with breast cancer in January 2016. Her treatment has included chemotherapy, radiation and surgery. Donnamarie's doctor, Dr. Erica Mayer, is the daughter of her husband's doctor, Dr. Bob Mayer treats Michael and Mayer's daughter, Dr. Erica Mayer, a breast oncologist in the Susan F. Smith Center for Women's Cancer at Dana-Farber, is treating Donnamarie.Dr. Mayer can talk about the advances made in colo-rectal cancer and the importance of men and women getting screened for this, as if caught early, it's a very curable disease. He's been on staff at Dana-Farber since 1974.  Besides his faculty leadership position, he continues to treat patients for gastrointestinal cancer, specializing in colon cancer.

Book Lights host Debra Parmley chats with NYT Bestselling author Bob Mayer about Independence Day and the Time Patrol series.  Bob Mayer is a NY Times Bestselling author of over 70 books, West Point graduate, former Green Beret and feeder of Cool Gus. Born in the Bronx, having travelled the world (not tourist spots), he lives peacefully with his wife (who collaborates with him). For more about Bob Mayer visit http://bobmayer.com and for more about host Debra Parmley visit http://debraparmley.com Book Lights - shining a light on good books!

Bob Mayer is a former Green Beret and traditionally published author turned indie. He has a long backlist (and frontlist) that includes military fiction, military science fiction and historical as well as a handful of collaborations with popular romantic comedy author Jennifer Crusie. We talked with Bob about how writing military fiction, co-write with an author from a completely different genre and how to be a self-published author. This was certainly an interesting show!

Bob Mayer is a West Point Graduate, Former Green Beret, CEO of Cool Gus Publishing and a NY Times Bestselling Author. He has had over 50 books published, and has sold over four million copies.  He is greatly in demand as a leadership speaker and consultant for his Who Dares Wins: The Green Beret Way concept. He is also the Co-Creator of Cool Gus Publishing, which does both eBooks and Print On Demand. Bob grew up in the Bronx. After high school, he entered West Point where he learned about the history of our military and our country. During his four years at the Academy and later in the Infantry, Mayer questioned the idea of "mission over men." When he volunteered and passed selection for the Special Forces as a Green Beret, he felt more at ease where the men were more important than the mission. Mayer's obsession with mythology and his vast knowledge of the military and Special Forces, mixed with his strong desire to learn from history, is the foundation for his science fiction series Atlantis, Area 51 and Psychic Warrior. His unique background in the Special Forces gives the reader a sense of authenticity and creates a reality that makes the reader wonder where fact ends and fiction begins. Bob has presented for over a thousand organizations both in the United States and internationally, including keynote presentations, all day workshops, and multi-day seminars. He has taught organizations ranging from writers, to law enforcement and even Fortune-500 companies. Websites: http://coolgus.com/ http://www.bobmayer.org/ Bob’s books on Amazon: http://www.amazon.com/s/ref=nb_sb_ss_c_0_9?url=search-alias%3Dstripbooks&field-keywords=bob+mayer&sprefix=bob+mayer%2Caps%2C217   Serving over 3 decades in the military as an Airborne Ranger, a Special Forces Operator, and finally as an Emergency Medicine Physician assigned to Special Operations, Mike Simpson is well acquainted with what it truly means to be a warrior.  As a board certified Emergency Medicine Physician, and a practicing fight doctor, Mike works extensively with Mixed Martial Arts (MMA) fighters, law enforcement, and military organizations providing medical care and training.  As one of the foremost experts in both tactical medicine and combat sports medicine, he is highly sought after as a lecturer and instructor.  Now, as host of the Mind Of The Warrior podcast, Mike shares his knowledge, and that of his guests, in an effort to spread to warrior ethos to the general public. Website: http://www.hoplonmedical.com Email: hoplonmedical@gmail.com Twitter: @MMA_Doctor

Bob Mayer, former U.S. Army Green Beret, best-selling author of the Green Beret and Area 51 series, and one of our Badass Writers of the Week, stops by the podcast to talk about how he started writing while learning martial arts in Korea, why up-and-coming writers need to learn more about the publishing business, and how his writing process has evolved over time.  

Bob Mayer—a NYT best-selling author and micro-publisher—discusses the forces at play in publishing today such as building your own team, keeping your rights, profiting from audio books, and more. Bob also talks about how he's bootstrapping his micro-publishing startup—Cool Gus Publishing—from the incredible revenue generated from his backlist of popular scifi series like Area 51. Oh, and Bob's a former Green Beret, so he's not messing around with the advice he gives. Listen up!

Green Beret and writer Bob Mayer talks about his books and the writer's life.

Today's super negotiator has to be a versatile problem solver, seeking hard-bargain results with a soft touch. With punch and panache, Bob Mayer shows you how to make the grade, revealing powerful negotiating tools drawn from a unique blend of sources:Recent advances in psychology, linguistics, trial advocacy, sales, and management communications-the cutting edge of the art of performance.Tips, tricks, and techniques from 200 of the world's masters-the legendary street and bazaar merchants of Bombay, Istanbul, Cairo, and Shanghai.Mayer's own "been there, done that" years as a lawyer representing thousands of clients (from foreign government agencies and mega-corporations to some of the world's best-known actors, authors, and athletes), negotiating deals on everything from amphitheaters to Zero aircraft.You'll learn what works-and what doesn't-when you're up against a stone wall…or your ideas are being rejected…or you're confronted with hostility and anger. Included is the highly acclaimed Deal Maker's Playbook, a collection of step-by-step "how-to's" and "what-to's" for 38 common negotiatingsituations such as:Buying a carLeasing an apartmentDealing with the IRS;Interviewing for a JobBuying a franchiseGetting out of debtIt's all here-the fancy footwork and magic moves for outgunning, outmaneuvering, and out-negotiating the other person. And the techniques for developing life skills that will dramatically enhance your chances of professional success and personal satisfaction. BiographyLarry King calls Bob Mayer "a lawyer's lawyer." He has appeared on over 130 radio and television shows and has conducted negotiating workshops for UCLA, the University of Southern California, Tulane University, Pepperdine University, various governmental authorities, private companies, and professional associations. He lives in Los Angeles.

Today's super negotiator has to be a versatile problem solver, seeking hard-bargain results with a soft touch. With punch and panache, Bob Mayer shows you how to make the grade, revealing powerful negotiating tools drawn from a unique blend of sources:Recent advances in psychology, linguistics, trial advocacy, sales, and management communications-the cutting edge of the art of performance.Tips, tricks, and techniques from 200 of the world's masters-the legendary street and bazaar merchants of Bombay, Istanbul, Cairo, and Shanghai.Mayer's own "been there, done that" years as a lawyer representing thousands of clients (from foreign government agencies and mega-corporations to some of the world's best-known actors, authors, and athletes), negotiating deals on everything from amphitheaters to Zero aircraft.You'll learn what works-and what doesn't-when you're up against a stone wall…or your ideas are being rejected…or you're confronted with hostility and anger. Included is the highly acclaimed Deal Maker's Playbook, a collection of step-by-step "how-to's" and "what-to's" for 38 common negotiatingsituations such as:Buying a carLeasing an apartmentDealing with the IRS;Interviewing for a JobBuying a franchiseGetting out of debtIt's all here-the fancy footwork and magic moves for outgunning, outmaneuvering, and out-negotiating the other person. And the techniques for developing life skills that will dramatically enhance your chances of professional success and personal satisfaction. BiographyLarry King calls Bob Mayer "a lawyer's lawyer." He has appeared on over 130 radio and television shows and has conducted negotiating workshops for UCLA, the University of Southern California, Tulane University, Pepperdine University, various governmental authorities, private companies, and professional associations. He lives in Los Angeles.

Bob Mayer, Special Forces veteran and NY Times best-selling author, will be here discussing how to apply Special Operations Tactics in the civilian world, particularly the creative field of writing.

Bob Mayer, Special Forces veteran and NY Times best-selling author, will be here discussing how to apply Special Operations Tactics in the civilian world, particularly the creative field of writing.